Introduction
============

Endometriosis is an enigmatic benign common gynecological condition defined as the presence of functional endometrium-like tissue (endometrial glands and stroma) in places outside the uterine cavity, primarily detected in the pelvic peritoneal cavity and ovaries. Although the exact incidence of endometriosis remains unknown, approximately 3--10% of women of reproductive age suffer from this chronic disease. More than 20% of women can be asymptomatic and may not undergo abdominal exploration or biopsy procedures. An accurate diagnosis requires the direct visualization of the pelvis during a thorough laparoscopic surgical observation. Based on current knowledge, up to 50% of women referred for fertility problems, 2--5% of postmenopausal cases and 10--70% of patients with pelvic pain are linked to endometriosis. Endometriosis is usually clinically manifested with chronic pelvic pain, dysmenorrhea, dyspareunia and subfertility ([@b1-etm-0-0-8296]--[@b3-etm-0-0-8296]).

The complexity of the pathogenesis and the pathophysiology of this disease are the reason for the existence of various controversies in the literature as regards the optimal effective treatment modality for endometriomas. The purpose of surgical management should focus on the confirmation of pre-operative diagnosis, the exclusion of malignant transformation, the relief of chronic pelvic pain, dysmenorrhea, dyspareunia or dyschezia and the preservation of future fertility. Surgery for endometriosis and endometrioma can be performed by laparotomy or laparoscopy, as both techniques result in similar symptom regression, fertility treatment, cyst recurrence and major complication rates. However, operative laparoscopy compared with laparotomy represents the gold standard method for the detection of endometriotic implants under magnification in the pelvis. Additionally, the laparoscopic approach offers a lower morbidity, minor post-operative adhesions and a lower duration of hospitalization with a significant better aesthetic result. However, in severe conditions when extensive adhesions or various organs are involved, laparotomy is preferred ([@b4-etm-0-0-8296]--[@b6-etm-0-0-8296]). Notably, an association between malignancy and endometriosis has been documented in the literature for a number of years ([@b7-etm-0-0-8296]). Recently, Kvaskoff *et al* observed an association of endometriosis, immune dysfunction, and common obstetric and gynecologic diseases ([@b8-etm-0-0-8296]). Furthermore, Teng *et al* observed that endometriosis was associated with higher comorbidities ([@b9-etm-0-0-8296]).

In this study, the authors aimed to investigate the epidemiological aspects of the surgical outcomes of endometriosis surgery from two different academic institutions and to further demonstrate the potential distribution of the diagnosis and important characteristics of endometriosis by institution.

Materials and methods
=====================

The present retrospective study involved 1,200 women (15--80 years of age) treated via laparotomy or laparoscopy, at two different institutions, for endometriosis, between 1990 and 2017. A total of 600 medical records of women with endometriosis were reviewed between 1996--2005, from the Division of Reproductive Endocrinology at Yale University School of Medicine and 600 cases, between 1990 and 2017, from the Department of Obstetrics and Gynecology of the University of Crete and the Department of Venizeleio General Hospital of Heraklion.

The Ethics Committee of Venizeleio Hospital (ECH\#46/6680; ECHR no. 47/773) and the Human Subjects Committee of Yale (HIC\#12590) approved the protocol. The stage of endometriosis was scored according to the revised classification of the American Fertility Society ([@b10-etm-0-0-8296]) and biopsy specimens were obtained to confirm the histological diagnosis. The following patient characteristics were recorded: Age, age at menarche, main complaints, obstetric outcome, family history, the stage of endometriosis and other important characteristics of endometriosis by institution.

The Student\' t-test and χ^2^ test were used for the comparisons of the mean of the various characteristics. The Mann-Whitney U test was performed if data were not distributed normally. The results are presented as the means ± SD or as percentages where appropriate. Differences were considered statistically significant at P\<0.05.

Results
=======

The patients with endometriosis from Greece were older (P\<0.02) in comparison with the women from Yale ([Table I](#tI-etm-0-0-8296){ref-type="table"}). Moreover, infertility (P\<0.01) was mostly observed in patients from Yale and gravida were less frequent among the Yale population (P\<0.01). All the other characteristics of all the women are presented in [Table I](#tI-etm-0-0-8296){ref-type="table"}. In the Yale and Greek populations, similar results were obtained as regards the site of endometrioma. The occurrence of left-sided endometrioma was found to be significantly higher in both groups.

The distribution of the diagnosis and important characteristics of endometriosis by institution are presented in [Table II](#tII-etm-0-0-8296){ref-type="table"}. No significant differences in endometriosis were observed following *in utero* exposure to diethylstilbestrol (DES), non-Hodgkin\'s lymphoma, endometriosis-associated Lyme disease, human immuno-deficiency virus (HIV) and melanoma and endometriosis in adolescents, between the two groups.

A statistically significant positive association (P\<0.001) was noted for the coexistence of benign gynecological tumors (apart from endometrioma), endometriosis-associated ovarian cancer and for postmenopausal endometriosis in women with endometriosis from Greece. However, when patients were analyzed according to the uterine anomalies in association with endometriosis, of note, a higher (P\<0.05) proportion was observed in the Yale population.

Discussion
==========

Although endometriosis is derived from the ancient Greek words endo (meaning inside), metra (womb) and iosis (meaning infection or viral disease), it was not described as several other gynecological conditions in the writings of Hippocrates, Soranus of Ephesus, or Aesculapius. Daniel Shroen was the first who described endometriosis, 320 years ago in his book entitled 'Disputatio Inauguralis Medica de Ulceritus Ulceri' ([@b11-etm-0-0-8296]), and has since been accepted as a chronic, painful and often progressive disease affecting women of reproductive age. Endometriosis is an invasive chronic non-cancerous condition and thus, the establishment of extrauterine sites of endometrial implantation requires that endometrial cells are capable of penetrating the mesothelium, or organs within, the peritoneal cavity.

The actual history of endometriosis began after the introduction of endoscopy in the 1970s, where diagnostic laparoscopy was performed for pain and infertility. A PubMed search with the key word, endometriosis, yielded a total of 24,855 articles. Using the combination of surgical endometriosis (laparoscopy and laparotomy) the search yielded 8,410 or 33.8% of the total literature on endometriosis (accessed January, 2018). It has been well established that endometriosis is still considered a primary surgical disease, despite the relevant accomplishment obtaining using hormone treatment ([@b12-etm-0-0-8296]). According to current knowledge, surgery represents the only treatment for cystic ovarian endometriosis or deep endometriosis, conditions which are associated with severe pain and infertility. Medical treatment can only inactivate endometriosis without reducing the size of the cyst ([@b4-etm-0-0-8296],[@b6-etm-0-0-8296],[@b13-etm-0-0-8296]).

Several retrospective cohort studies have focused on the surgical outcomes of women with endometriosis operated by laparoscopy or laparotomy. These studies have demonstrated that the ideal and most effective conservative laparoscopy technique for the management of endometriosis remains a controversial issue in the literature ([@b14-etm-0-0-8296]--[@b16-etm-0-0-8296]). As reported by the literature, cystectomy should be the choice of surgical treatment at the end of the reproductive age or for those with repeated previous operations for endometriosis. Conservative laparoscopic cystectomy seems to be superior to drainage or coagulation in reducing symptoms and recurrence. Although it may damage ovarian follicle reserve, it improves subsequent spontaneous pregnancy rates. Women who experience severe and deep endometriosis and do not have a desire for future pregnancy, are candidates for bilateral salpingo-oophorectomy and hysterectomy.

In the current study, endometrioma was found in 359 (29.9%) of cases. The two groups of patients had similar rates of the stage of endometriosis and the site of endometrioma. Furthermore, in the Greek population, a coexistence of benign gynecological tumors, endometriosis-associated ovarian cancer and post-menopausal women with endometriosis was observed, which was significant in comparison with the Yale population.

Mutations of the mammalian target of rapamycin (mTOR) signaling pathway have been found to be involved in the development of endometrial cancers ([@b17-etm-0-0-8296]). Contrarily, data have indicated no association of checkpoint kinase 2 (*CHEK2*), Erb-B2 receptor tyrosine kinase 2 \[commonly referred to as *HER2*; (*RBB2*)\] or *ATM* with an increased risk of developing endometrial cancer ([@b18-etm-0-0-8296],[@b19-etm-0-0-8296]). In endometrial cancers, somatic mutations are frequent in the MutL homolog 1 *(MLH1), MSH2*, MutS homolog 6 (*MSH6*), phosphatase and tensin homolog (*PTEN*), *KRAS* and *β-catenin* genes in type I carcinomas ([@b20-etm-0-0-8296]). Although the genetics of benign gynecological tumors ([@b21-etm-0-0-8296]) and endometriosis-associated ovarian cancer have been extensively studied, genetic analyses focusing on the predisposition for post-menopausal endometriosis are limited. In fact, it is important to be aware of a putative genetic background that may contribute to the development of postmenopausal endometriosis, given that it infers a risk of malignant transformation ([@b22-etm-0-0-8296]). Postmenopausal women produce estrogen by the steroidogenic gene aromatase that is expressed in stromal cells in endometriosis, and aromatase inhibitors are used to treat postmenopausal endometriosis by suppressing local estrogen production ([@b23-etm-0-0-8296]). Furthermore, it has been reported that single nucleotide polymorphisms (SNPs) in the DNA base excision repair (BER) system, such as the X-ray repair cross complementing 1 (*XRCC1*) gene, which has been extensively studied in the association with various types of cancer, harbors an Arg399Gln polymorphism playing an important role in endometrial cancer development in postmenopausal women in a Polish, as well as in a Japanese population ([@b24-etm-0-0-8296],[@b25-etm-0-0-8296]). *TP53* Arg72Pro polymorphism has also been reported to be a prognostic factor for endometrial cancer in postmenopausal women ([@b26-etm-0-0-8296]).

In a previous study, it was observed that endometriosis may be associated with an increased risk of benign gynecological tumors, such as ovarian cysts, adenomyosis and leiomyomas ([@b21-etm-0-0-8296]). These findings are not surprising, considering that various shared genetic factors have been detected for endometriosis and leiomyoma, i.e., the +2073 A/T polymorphism of the epidermal growth factor receptor (*EGFR*) gene and the angiotensin I converting enzyme (*ACE*) I/D polymorphism ([@b27-etm-0-0-8296],[@b28-etm-0-0-8296]) or endometriosis and adenomyosis, i.e., polymorphisms of the catechol-*O*-methyltransferase (*COMT*), cytochrome P450 family 1 subfamily B member 1 (*CYP1B1*), cyclooxygenase-2 *(COX-2)*, vascular endothelial growth factor (*VEGF*), matrix metalloproteinase-1 *(MMP-1)* and *MMP-7* genes ([@b29-etm-0-0-8296]--[@b33-etm-0-0-8296]). Additionally, the results of the aforementioned study confirmed a left lateral predisposition of endometriomas and ovarian cysts ([@b21-etm-0-0-8296]). Moreover, apart from the similar co-morbidities described for adenomyosis and endometriosis ([@b34-etm-0-0-8296]), it has been suggested that the two conditions may have a similar pathogenesis due to a combination of genetic and epigenetic alterations ([@b35-etm-0-0-8296]), as shown also by data collected upon differential proteomic analysis by iTRAQ technique ([@b36-etm-0-0-8296]). Taken together, the results suggest that patients suffering from endometriosis should be counseled about the future risks of developing several gynecological diseases.

Furthermore, the present study detected similar results on non-Hodgkin\'s lymphoma, endometriosis-associated Lyme disease, HIV, melanoma and endometriosis in adolescents between the two groups. Of note, the authors have recently reported an association between endometriosis in adolescents and young women, and risk factors including early menarche, early onset of dysmenorrhea, history of asthma, previous surgical procedures, obstructive genital anomalies, and family history of endometriosis. The demographic observations in this series may reflect a diagnostic bias for endometriosis in the young population who suffers from dysmenorrhea and chronic pelvic pain ([@b37-etm-0-0-8296]). Notably, several academic studies have noted an association between endometriosis and other severe chronic diseases ([@b8-etm-0-0-8296],[@b9-etm-0-0-8296],[@b38-etm-0-0-8296],[@b39-etm-0-0-8296]).

In conclusion, the current study reported similar characteristics in both institutions as regards the surgical outcomes on endometriosis surgery. Of note, women with endometriosis have higher co morbidities, including benign and malignant disease. Based on these outcomes, it is thus recommended that clinicians should pay more attention to the combined management of such cases and to further to follow-up all cases operated for endometriosis on a long-term basis, since endometriosis can coexist with other medical diseases.
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###### 

Distribution of menstrual, clinical and reproductive characteristics of 600 women with endometriosis from Yale center and 600 cases with endometriosis from the Greek population.

  Characteristic                             Women with endometriosis from Yale (n=600)                       Women with endometriosis from Crete (n=600)                      P-value^[a](#tfn1-etm-0-0-8296){ref-type="table-fn"}^
  ------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------
  Age in years, median (range)                 32.5±6.6 (15--56)                                              36.3±8.2 (19--80)                                                \<0.02
  Age at menarche in years, median (range)   12.2±1.4 (9--18)                                                 12.1±1.3 (10--17)                                                N.S
  Main complaints (%)                                                                                                                                                          
    Infertility                                325/600 (54.2%)                                                150/600 (25%)                                                    \<0.01
    Pelvic pain                                320/600 (53.4%)                                                  308/600 (51.3%)                                                N.S
  Stage of endometriosis                                                                                                                                                       
    I                                          101/600 (16.8%)                                                  95/600 (15.8%)                                                 N.S
    II                                         179/600 (29.8%)                                                  169/600 (28.2%)                                                N.S
    III                                        147/600 (24.5%)                                                  161/600 (26.8%)                                                N.S
    IV                                         173/600 (28.9%)                                                  175/600 (29.2%)                                                N.S
  Endometrioma (%)                             185/600 (30.8%)                                                174/600 (29%)                                                    N.S
    Left-sided                                 99/151 (65.5%)                                                   94/143 (65.7%)                                                 N.S
    Right-sided                                52/151 (34.5%)^[b](#tfn2-etm-0-0-8296){ref-type="table-fn"}^     49/143 (34.3%)^[b](#tfn2-etm-0-0-8296){ref-type="table-fn"}^   N.S
    Bilateral                                34                                                               31                                                               N.S
  Gravida                                                                                                                                                                      
    0                                          255/600 (42.5%)                                                  91/600 (15.2%)                                                 \<0.01
    ≥1                                         345/600 (57.5%)                                                  509 (84.8%)                                                    \<0.01
  Family history of endometriosis              54/600 (9%)                                                      59/600 (9.8%)                                                  N.S

P-values derived from comparisons between the two groups (Yale vs. Crete populations)

P\<0.001, indicates significant difference between left- and right-sided endometrioma within each population group. Data are presented as n (%) or as the mean ± SD. N.S, not significant.

###### 

Distribution of the diagnosis and important characteristics of endometriosis by institution.

  Characteristic                                                       Yale (n=600)      Crete (n=600)     P-value
  -------------------------------------------------------------------- ----------------- ----------------- ---------
  Endometriosis following *in utero* exposure to DES (%)               7/600 (1.2%)      0/600 (0%)        N.S
  Uterine anomalies in women with endometriosis                        19/600 (3.2%)     7/600 (1.2%)      \<0.05
  Non-Hodgkin\'s lymphoma (%)                                          12/600 (2%)       3/600 (0.5%)      N.S
  Endometriosis-associated Lyme disease                                5/600 (0.9%)      1/600 (0.2%)      N.S
  Human immunodeficiency virus (HIV)                                   1/600 (0.2%)      2/600 (0.3%)      N.S
  Coexistence of benign gynecological tumors except endometrioma (%)   133/600 (22.1%)   265/600 (44.1%)   \<0.001
  Endometriosis-associated ovarian cancer                              3/600 (0.5%)      23/600 (3.9%)     \<0.001
  Endometriosis and melanoma                                           3/600 (0.5%)      2/600 (0.3%)      N.S
  Endometriosis in adolescents (13--20 years old)                      21/600 (3.5%)     29/600 (4.8%)     N.S
  Postmenoposal endometriosis (52--80 years old)                       14/600 (2.3%)     31/600 (5.2%)     \<0.001

Data are presented as n (%). N.S, not significant.
